Sisram Medical Ltd (1696) Fair Value & Analysis
Healthcare · HK · Market cap HK$1.1B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 3 days ago
Share price −4.2% over the past month.
A solid business, but screening 61% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$1.12). The favourable scenario is already priced in.
- Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (HK$0.5900 to HK$1.12) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$2.15 – HK$27.70 · fair‑value band HK$0.5900 – HK$1.12 · the HK$2.28 price screens above the HK$0.8900 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Sisram Medical Ltd (1696) currently trades at HK$2.28, while our model-based Fair Value estimate is HK$0.8900, implying the stock looks roughly 61.0% overvalued today. The Quality Score stands at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Sisram Medical Ltd generated revenue of HK$365M at a net margin of 5.2%. Revenue grew 10.8% year over year. It earns a return on equity of 5.1%. The balance sheet holds a net cash position of HK$19.2M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.5900 (bear case) to HK$1.12 (bull case); at HK$2.28, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 71% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at -61%, 1696 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (HK$0.9600) versus Dividend Discount (HK$0.2100). Highest evidence: Growth DCF (80).
Notify me when 1696 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 20
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sisram Medical Ltd, together with its subsidiaries, engages in the research, design, development, manufacture, sale, and marketing of medical aesthetics and dental equipment, home-use devices, injectables, and cosmeceutical products in the Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America.
Full company description
Sisram Medical Ltd, together with its subsidiaries, engages in the research, design, development, manufacture, sale, and marketing of medical aesthetics and dental equipment, home-use devices, injectables, and cosmeceutical products in the Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America. The company offers a portfolio of products and treatments for clinical aesthetic indications, including hair removal, skin rejuvenation, acne and acne scars, trans-epidermal delivery, face and body contouring, cellulite treatment, stretch marks, vascular and pigmented lesions, pigmentation and skin resurfacing, fat grafting, dermal facial fillers, skin tissue remodeling, injectables, personal care, aesthetic dentistry, hydradermabrasion, blepharoplasty (nonsurgical eyelid lift), liposuction, feminine health, and sexual rehabilitation. It also engages in pharmaceutical research and development activities. The company offers its products under the Alma, LMNT, Copulla, Profhilo, and Aliaxin brands. Sisram Medical Ltd was founded in 1999 and is headquartered in Caesarea, Israel.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sisram Medical Ltd reported revenue of HK$365M in FY2025 versus HK$294M in FY2021, a compound +5.6%/yr. Reported net income was HK$19.0M in FY2025, compounding −11.7%/yr from FY2021.
of which total revenue +14.0 pp · buybacks/dilution −1.9 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
1696 screens 61% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 350 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.60 | ¥147.63 | -4% |
| Shanghai United Imaging Healthcare Co 688271 | ¥110.50 | ¥43.60 | -61% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 239.30 | kr 192.14 | -20% |
| Sectra AB SECTB | kr 280.00 | kr 66.81 | -76% |
Compare Sisram Medical Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sisram Medical Ltd (1696) overvalued or undervalued?
What is the fair value of 1696?
What is the quality score of 1696?
What is the revenue of Sisram Medical Ltd (1696)?
What is the net profit margin of 1696?
Does Sisram Medical Ltd pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sisram Medical Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.